Laboratory Aspects Relating to the Detection and Prevention of Frailty

Hans-Jürgen Heppner1, Jürgen M. Bauer1*, Cornel C. Sieber1, Thomas Bertsch2

1 MD, Department of Internal Medicine 2, Nuremberg Clinic, Chair of Internal Medicine V, Geriatrics and Institute for Biomedicine of Ageing, Friedrich Alexander University Erlangen-Nuremberg, Nuremberg, Germany.
2 MD, Institute of Clinical Chemistry, Laboratory Medicine and Transfusion Medicine, Nuremberg Clinic, Germany.
*Contributed equally

Correspondence to:
Prof. Dr. Thomas Bertsch, Nuremberg Clinic, Institute of Clinical Chemistry, Laboratory Medicine and Transfusion Medicine, Prof. Ernst-Nathan-Strasse 1, 90419 Nuremberg, Germany.
Email: thomas.bertsch@klinikum-nuernberg.de

ABSTRACT

Frailty, as a geriatric syndrome, is characterized by the increased vulnerability of the elderly person to internal and especially external stressors. The aim of laboratory diagnostics in the context of the concept of frailty is to record the conditions which encourage the development of frailty, in order to improve these conditions through individual measures or to avoid them for the purpose of preventing frailty. After a presentation of the features of laboratory diagnostics in old age, this article examines haematological aspects, the importance of an adequate vitamin supply, particularly of vitamin D and the adequate description of endocrine functions.

Keywords: Frailty; Laboratory diagnostics; Vitamins; Hormones; Cytokines.

FEATURES OF LABORATORY DIAGNOSTICS IN OLD AGE

Frailty is a geriatric syndrome which is characterized by increased vulnerability of the elderly person to internal and especially external stressors (including mitochondrial oxidative stress, diseases, side effects of drugs, mental and social stresses). It is closely associated in its development with age-related loss of muscle mass, sarcopenia, and is accompanied by an increased risk of loss of independence, hospitalisation and mortality.1,2 The various stages of frailty form a continuum between complete independence on one side and the presence of a disability on the other (Figure 1). Early stages of frailty can only be detected with the aid of specific tests, while later stages are clinically apparent as a result of significant losses of function. The Fried definition for the phenotypic character of frailty proposes five items: weight loss, exhaustion, weakness, slow walking speed and low levels of physical activity (Table 1). Frailty is diagnosed when at least three criteria are met. An individual is said to be pre-frail when one or two of these criteria are present. Based on the results of several recent studies, the weight loss criterion may be corrected to weight change as higher BMI values above 30 kg/m² were associated with a loss of functionality which may be an expression of becoming frail. For the calculation of the Frailty Index by Rockwood, it is necessary to count the deficits that are present in an individual.3 In the most extensive study, Rockwood and co-workers have published yet 70 deficits that were used for evaluation. These included active diseases, disabilities in the activities of daily living and physical signs from the clinical and neurological examinations. The clinical applicability of these two measures has to be regarded differently. While the Fried criteria concentrate on the physical aspects of frailty and are more easy and quick to work with, the Frailty index by Rockwood incorporates a more diverse spectrum of information on the elderly individual and therefore requires a more elaborate work up. Although there are scores for the description of the frailty syndrome, Ferrucci and co-workers stated4: “The definition of frailty is at an early stage. Recent studies suggest that the frailty syndrome is a physiological state of susceptibility that places older individuals at high risk of rapid deterioration of health and functional status. Multiple medical conditions, age and disease may contribute to the activation of a cyclic, self-sustained pathophysiological path-
way that, over the short term, causes physical
impairment, functional limitation and severe
disability. The factors that contribute to this
cyclic metabolic pathway, currently defined as
the frailty syndrome, are still unclear and, there-fore, there is still uncertainty on what circulating
molecules should be considered as biomarkers of
frailty”. Although there are a lot of candidates
for biomarkers, we focus our review article on
the description of laboratory parameters which
are available in most clinical routine laborato-
ries. So that with the means of these easily
available laboratory parameters, an alteration of
function in the organ systems can be detected
and the occurrence of the frailty syndrome
might be decelerated. Only at the end, we give
an outlook to new biomarkers from the cytokine
family.

Table 1. Criteria for the phenotypic definition of frailty developed by Fried et al.1

| Criteria                  | Definition                                      |
|---------------------------|-------------------------------------------------|
| Weight loss               | >5 kg/year                                      |
| Exhaustion                | Depression scale CES-D (2 points)               |
| Weakness                  | Grip strength (lowest 20%)                      |
| Gait speed                | 5 m (slowest 20%)                              |
| Low physical activity     | Kcal/week (lowest 20%)                         |
| Diagnosis of frailty      | 3 or more criteria met                          |
| Diagnosis of pre-frailty  | 1-2 criteria met                                |

Figure 1. Trajectories of performance over the lifespan. The two curves represent “normal” ageing and “acceler-
ated ageing” (modified after 4).

The aim of laboratory diagnostics in every-
day medical practice in relation to frailty syn-
drome is to record predisposing factors for the
development of the frailty syndrome, in order to
make it possible to introduce the appropriate
therapy. This should prevent the functional slide
into an advanced stage of frailty and the devel-
opment of a manifest disability. Essentially,
there are two approaches in laboratory medi-
cine: on the one hand, the patients’ results are
compared at a certain point in time with the so-
called “normal values” or “reference ranges”
(cross-sectional assessment, screening). On the
other hand, it is also possible to assess the
changes in a value measured in the laboratory
over the course of time in one patient. This is
then referred to monitoring. Establishing refer-
ence intervals in Geriatrics is essentially diffi-
cult, since in the course of life a variety of nox-
ious substances specific to the individual (alco-
hol, tobacco, inflammations, toxins etc.) result
in a quite individual change in the body’s bio-
chemistry and its physiological properties.5,6

Nevertheless, an attempt was made to establish
reference intervals as a guide for the most vary-
ing values measured in the laboratory, which are
helpful as a working basis. The book Geriatric
Clinical Chemistry by Faulkner and Meites7 is
recommended, which lists method-oriented est-
blished values measured in the laboratory
graded according to the age in years. However,
the limitation mentioned above should always
be borne in mind when interpreting the labora-
tory values of the elderly. Because of the age-
associated changes and the associated difficulties
in comparing them with reference intervals,
laboratory diagnostics of the elders should con-
centrate not so much on identifying a sick per-
son from a collective of essentially healthy peo-
ple, but rather on evaluating the dynamics of the
pattern of laboratory values. This dynamic ap-
proach would also make it possible to give con-
sideration to the kinetics and the consequences
of the “ageing process”. The dynamic approach
means also an “individualistic approach” is
needed where individual factors and stressors
that occurred over lifetime should be taken into
account to develop specific prevention strategies
which are adapted to the patient and its present
situation. There now follows a discussion of a
few special measured values which play a spe-
cific role in the context of frailty syndrome.

DIAGNOSIS OF ANAEMIA

According to the definition of the World
Health Organisation, anaemia is present when
the haemoglobin concentration in blood in
women is less than 12 g/dL and in men less
than 13 g/dL. Based on these criteria, the preva-
ience of anaemia in over 65-year-olds in various
populations is between 8 and 44%. In a major US study, the prevalence in over 80-year-olds was 26% in men and 20% in women. In the vast majority of all cases, there are mild degrees of anaemia. The presence of anaemia is associated in the elderly with a marked increase in mortality. This has been demonstrated both for elderly people living independently and for the population of retirement homes. In the presence of certain comorbidities such as chronic heart failure or cancer, anaemia causes an added increase in mortality. Anaemia in the elderly is associated with an increased likelihood of deterioration in their physical capability and loss of their independence. Furthermore, a link has been established with the frequency of falls. Chaves and colleagues also demonstrated a direct link in elderly women between the evidence of anaemia and the presence of frailty. This link was apparent even in low normal Hb values. Although all these studies demonstrated an association between anaemia and frailty, a causal relationship between these two entities has not yet been adequately established. In many cases of simultaneous frailty and anaemia, it is highly likely that the latter is an epiphenomenon. Nevertheless, clarifying the cause of anaemia in old age is of important clinical significance.

The causes of anaemia in old age are varied. Special mention should be made of anaemia in chronic diseases such as malignancies, chronic infections, collagenosis, chronic inflammation, heart failure and diabetes mellitus. This form of anaemia is the most common form in old age. Around one third of all cases of anaemia in old age are caused by nutritional factors. Here, iron deficiency is of particular significance. The most important criterion to distinguish anaemia caused by chronic inflammation and that caused by iron deficiency is the serum concentration of the iron storage protein, ferritin, which is lowered as a sign of lack of storage iron in iron deficiency anaemia, and raised in anaemia of chronic diseases. One reason for the increase in ferritin is its capacity to react in inflammatory processes as a so-called acute-phase protein, similarly to the C-reactive protein. This form of anaemia is characterised by well-filled macrophagocytic iron stores, which cannot however be used in sufficient measure for haemoglobin synthesis. Another cause of anaemia which is avoidable with adequate vitamin substitution is vitamin B12 or folic acid deficiency anaemia. As a result of impaired DNA metabolism, macrocytic, hyperchromic anaemia develops, which is characterised by an increased mean erythrocyte volume with a simultaneously high haemoglobin content of the erythrocytes. Matteini and co-workers found in a cross-sectional study of baseline measures from the combined Women’s Health and Aging Studies that vitamin B12 deficiency may contribute to the frailty syndrome in community-dwelling older women. For prevention of the frailty syndrome, adequate vitamin B12 substitution seems to be important.

Although the cause of anaemia in old age cannot always be reliably explained in every case, nevertheless a few simple laboratory tests allow the causes to be narrowed down as far as possible by differential diagnosis (Table 2). The practical impact of the aforementioned “kinetic approach” can be explained by a study of Ferrucci et al. This study demonstrated that patients with low testosterone levels had a higher risk to develop anaemia within 3 years. As a consequence, in patients with low testosterone serum levels, the haemoglobin values should be monitored.

### Table 2. Causes of anaemia in old age with the relevant values measured in the laboratory to narrow down the causes (main findings).

| Anaemia                                      | Value measured in the laboratory |
|----------------------------------------------|----------------------------------|
| Chronic inflammatory diseases                | Ferritin ⇑                        |
| Dietary iron deficiency                      | Ferritin ⇑                        |
| Vitamin B12 and folic acid deficiency        | MCV ⇑, vitamin B12 ⇑, folic acid ⇑|
| Chronic lymphatic leukaemia                  | Blood count                       |
| Myelodysplastic syndrome                     | Examination of bone marrow       |

### VITAMIN DETERMINATION

The importance of vitamin B12 and folic acid in the development of anaemia has already been explained in the previous section. Another vitamin which is attracting increasing attention in terms of its importance for the functionality of the elderly is vitamin D3. "Previtamin D3 is produced by the UV radiation from sunlight by photolytic conversion of 7-dehydrocholesterol; this previtamin is converted into vitamin D3 (cholecalciferol) by thermal isomerisation." The 25-hydroxyvitamin D3 is then formed in the liver by the cytochrome-system by means of 25-hydroxylation. This step is weakly regulated and correlates with the vitamin D3 intake or...
synthesis. For this reason and because of its high concentration, 25-hydroxyvitamin D3 compared with the active 1,25-dihydroxyvitamin D3 is a good indicator of the vitamin D3 status. The actually biologically active 1,25-dihydroxyvitamin D3 is produced by the 1-alpha-hydroxylation in the kidney (Figure 2). The transport protein megalin is responsible for the renal uptake of 25-hydroxyvitamin D3. The lipophilic 1,25-dihydroxyvitamin D3, bound to a transport protein, reaches the target organs from the kidney. This 1-alpha-hydroxylation step takes place not only in the kidney, also in many other body cells (mammary gland cells, prostate cells, colon cells, β-cells of the pancreas, cells of the immune system) (Table 3). The 1,25-dihydroxyvitamin D3 produced in these cells works mainly locally using autocrine and paracrine mechanisms to inhibit cell proliferation, facilitate cell differentiation and immunoregulation (Table 3). The hormone is degraded by 24-hydroxylation, which results in side-chain shortening. The 1,25-dihydroxyvitamin D3 develops its action, like the classic steroid hormones, via an intracellular receptor which, filled with 1,25-dihydroxyvitamin D3, then binds to the DNA and there modifies the gene transcription rate, after interaction with various co-factors. However, non-genomic rapid effects, as with steroid hormones, can also be demonstrated. The most important task of the vitamin D system is the regulation of calcium metabolism. The 1,25-dihydroxy vitamin D3 in the intestinal cells brings about the induction of transport proteins, which enable calcium to be absorbed in the intestine. As a result of the synergistic action of 1,25-dihydroxyvitamin D3 on the osteoblasts and osteoclasts, this enterally absorbed calcium is incorporated into the skeleton and thus bone mineralization is stimulated. However, vitamin D also works at other switch points of calcium homeostasis, such as in the kidney. The close connection between the vitamin D system and calcium or bone metabolism also explains the causal connection between vitamin D deficiency and rickets in children or osteomalacia in adults. In recent years, there have been increasing indications that the vitamin D system plays an important role in the metabolism of a wide variety of organ cells in a number of functional levels such as apoptosis; and that vitamin D3 deficiency is associated with diseases such as hypertension, diabetes mellitus, and various cancers (prostate cancer, breast cancer, colon cancer). Recommended reviews on this topic have been written by Dusso and colleagues, Grant and Holick and also Adams and Hewiston. The significance of vitamin D for these diseases becomes even more important in view of the fact that a large proportion of the population in Europe and North America has a marked 25-hydroxyvitamin D3 deficiency. In addition to the general habit of “staying out of the sun” for melanoma prophylaxis and a working life increasingly spent indoors, dietary factors and increasing air pollution are held responsible for this deficiency. Another topic under consideration is the provision of vitamin D3 to an increasingly elderly population. In a major study in
over 65-year-olds, Trivedi and colleagues showed that the additional intake of 300,000 IU vitamin D3/year reduced the fracture rate in the lower arm, spine and femur neck by more than 33%. The fact that vitamin D3 is not only important for the regular bone structure but also for muscle strength could be demonstrated in a meta-analysis by Bischoff and colleagues who showed that a supplemental vitamin D in a dose of 700-1000 IU a day reduced the risk of falling among older individuals by 19%. This shows the importance of adequate vitamin D3 provision for the elderly population. In our own unpublished study, we showed that virtually 80% of a sample of 70 outpatients over the age of 65 had 25-hydroxyvitamin D3 concentrations below 30 ng/mL. From the age of 70 onwards, a 25-hydroxyvitamin D3 serum level of 30-70 ng/mL can be regarded as optimum. Below this range there can be a latent decline in the serum calcium concentration, which triggers secondary hyperparathyroidism with facilitation of osteoporotic changes. Furthermore, numerous studies point to the importance of adequate vitamin D3 provision for good muscle function in old age, which again is associated with the risk of frailty. It is therefore recommended, also with regard to the prophylaxis of frailty, that serum 25-hydroxyvitamin D3 concentrations to be measured in healthy people from the age of 50 onwards regularly between January and April, as 25-hydroxyvitamin D3 serum concentrations are lowest at these times. As described above, measuring the 25-hydroxyvitamin D3 serum level is the best means of detecting vitamin D3 deficiency. The LC-Tandem mass spectroscopy serves as a reference method, where the HPLC and the immunoassay should be calibrated. The immunoassay has the advantage over the chromatographic method because of the higher sample flow-rate and the lower demands on personnel and equipment. However, certain disadvantages must be taken into account, such as the non-quantitative dissolving of the analyte out of its binding protein, which presents a challenge for the assay developer. A good comparison between the various immunoassays compared to the reference method was published by Roth and colleagues. In the coming years, our knowledge about the role of the vitamin D system, especially outside bone metabolism, will continue to grow, which in the light of the widespread vitamin D deficiency will result in more frequent requests for analysis.

### Table 3. Effects of 1-alpha hydroxylation in various organ systems.

| Site of 1-alpha hydroxylation | Action                                      |
|------------------------------|---------------------------------------------|
| Kidney                       | Endocrine actions: bone metabolism           |
|                              | intestinal Ca transport                     |
|                              | renal Ca transport                          |
|                              | blood pressure                             |
| Prostate, colon, breast,     | Autocrine/paracrine actions:                |
| immune cells, beta-cells,    | inhibition of cell proliferation           |
| skin                         | promotion of cell differentiation           |
|                              | immune regulation                          |

### HORMONE VALUES

The thyroid hormones play a central role in the metabolism, also with regard to the muscle function of the elderly period. Stimulated by the pituitary thyrotropin releasing hormone (TRH), there is a hypophysial secretion of the thyroid-stimulating hormone (TSH), which in turn stimulates the secretion of the thyroid hormone triiodothyronine (T3) and thyroxin (T4). These hormones react by way of a negative feedback mechanism on the secretion of TSH and TRH. Some of the clinical symptoms of a thyroid function disorder in old age are not very pronounced and often have an unspecific character. This makes clinical diagnosis difficult, especially as the clinical symptoms caused by thyroid dysfunction are often misinterpreted by the patients or their relatives as being age-related. This diagnostic dilemma justifies early examination of the TSH serum level where symptoms are unclear. If the level is pathological, the concentration of free thyroxin (fT4) and free triiodothyronine (fT3) should be measured. If these concentrations are normal and the TSH level is pathological, depending on the TSH level, this condition is referred to as latent or subclinical hyper- or hypothyroidism. If the concentrations of both thyroid hormones and also the TSH level are pathologically altered, this situation is referred to as manifest hypo- or hyperthyroidism. Adequate correction of pathological thyroid function represents an important cornerstone in avoiding and preventing the symptoms of frailty, as pathological thyroid hormone values have been demonstrated to be associated with impaired functionality in the elderly. Reference should be made in this context to articles by Weissel.
and Habra and Sarlis in relation to further clinical consequences and the therapeutic approach. The treatment of thyroid disease is another example to explain the “kinetic or individualistic” approach. Although there is still debate on the decision to treat or not to treat subclinical thyroid disorders, current recommendations state the necessity of considering treatment on an individual basis according to the symptomatology and to the possible benefits the older person may obtain.

A further component in the hormonal system, which shows marked changes in old age, is represented by the sex hormones. The effects of oestrogen deficiency in the pathogenesis of osteoporosis with its consequences (bone fractures) are generally known and therefore are not discussed further here. Instead, the diagnosis of testosterone deficiency in men should be examined in more detail. There is a continuous decline in serum testosterone concentration in the ageing man, although it is not possible to define such a clear turning point, like the drop in oestrogen at the onset of the menopause in women. The slow, continuous loss means that the symptoms of androgen deficiency such as reduction of muscular strength, lack of drive, and increased body fat are only gradually perceived.

In addition to the global reduction of testosterone, the amplitude of circadian rhythms with the highest values in the early morning, as is common in young men, declines. Testosterone is transported in the serum bound mostly to sex hormone-binding globulin (SHBG) and albumin. A number of factors affect hepatic SHBG and albumin production (hepatitis, liver cirrhosis, nephrotic syndrome), so that although the total testosterone is altered, the free, biologically active testosterone can remain in the normal range if testicular function is intact. For example, low total testosterone concentrations along with low SHBG concentrations can involve a normal concentration of free, active testosterone; so that in this case testosterone deficiency cannot be assumed. This means that the SHBG and albumin concentration should also be measured whenever testosterone is measured, particularly in patients with concomitant diseases. A calculated free testosterone (using SHBG, albumin and testosterone) can be used as a proxy for measuring free testosterone which is the active form of the hormone. It should be recognized that changes in binding characteristics of SHBG with aging make this calculation slightly inaccurate. The calculation of free testosterone is available at www.issam.ch.

The correct assessment or interpretation of the testosterone serum level is important in that it is assumed that disrupted “syncrinology” of the steroid hormones (dehydroepiandrosterone, testosterone and cortisol) in the ageing man can be regarded as a precursor of frailty and a reduced testosterone serum level results in a decline in gross muscular strength. Several age-related hormonal changes have been linked to the frailty syndrome and to its components. Among the latter, the hormonal relationship with the decrease of muscle strength received most attention. While testosterone, growth hormone and insulin-like growth factor I were most intensely studied in this context, open questions still remain with regard to clinical relevance and replacement therapy.

**INFLAMMATORY CYTOKINES**

A predominant role has also been attributed to inflammatory mechanisms and especially molecules from the cytokine family. Cytokines play a key role in ageing and are central factors in the pathogenesis of cachexia. Increased CRP-values, an induction product produced in the liver by interleukin-6, and proinflammatory cytokines like interleukin-6 were associated with the presence of frailty. Thus, these immune mediators possibly contribute to aggravating the comorbidities of these patients and to an increase in frailty.

**OUTLOOK**

By measuring the established and newer measured values presented in this article, such as cytokines, and the examination of their relationships with the functionality of the elderly, the continuing growth of knowledge about the development of frailty and the therapeutic options can be expected in the coming years. In recent years, chronic inflammatory processes associated with a reduction in muscle mass have increasingly been identified as pathogenetic components in the origin and perpetuation of frailty, and thus the hope of acquiring new knowledge which is also relevant for clinical routine practice by determining new measured values of the immune system like cytokines, does not appear to be unjustified. The article closes with this outlook on future measured values which are probably becoming important in the assessment.
by laboratory diagnostics and in the prevention of frailty. In conclusion, it can be stated that laboratory diagnostics, in addition to clinical observation and anthropometric data, represent an important component for the clarification of the causality of frailty and of the preventive approaches.

Conflict of interest statement: All authors declare that they have no conflict of interest.

Sources of funding: No source of funding.

REFERENCES

1. Fried LP, Tangen CM, Walston J, Newman AB, Hirsch C, Grottiener J, et al. Frailty in older adults: evidence for a phenotype. J Gerontol A Biol Sci Med Sci 2001; 56(3): M146-M156.
2. Bertsch T, Alber B, Bauer JM. Laboratory tests in the elderly and their relationship with frailty. Ther Umsch 2008; 65(8): 431-5.
3. Rockwood K, Song X, MacKnight C, Bergman H, Hogan DB, McDowell I, et al. A global clinical measure of fitness and frailty in elderly people. CMAJ 2005; 173(5): 489-95.
4. Ferrucci L, Cavazzini C, Corsi A, Bartali B, Russo CR, Lauretani F, et al. Biomarkers of frailty in older persons. J Endocrinol Invest 2002; 25(10 Suppl): 10-15.
5. Lapin A. Geriatrie: was ist normal im alter? stehen wir vor einem paradigmenwechsel in der laboratoriumsmedizin? Geriatries: what is normal in the aged? Should we expect a paradigm shift in laboratory medicine? Journal of Laboratory Medicine 2007; 31(1): 2-7
6. Lapin A, Bohmer F. Laboratory diagnosis and geriatries: more than just reference intervals for the elderly.. Wien Med Wochenschr 2005; 155(1-2): 30-5.
7. Faulkner WR, Meites S, American Association for Clinical Chemistry, Foundation M, Vanderbilt University. School of Medicine. Geriatric clinical chemistry: reference values. Washington: AACC Press; 1994. p. 187-607.
8. Salive ME, Cornoni-Huntley J, Guralnik JM, Phillips CL, Wallace RB, Ostfeld AM, et al. Anemia and hemoglobin levels in older persons: relationship with age, gender, and health status. J Am Geriatr Soc 1992; 40(5): 489-96.
9. Daly MP. Anemia in the elderly. Am Fam Physician 1989; 39(3): 129-36.
10. Joosten E, Pelemans W, Hiele M, Noyen J, Verhaeghe R, Boogaerts MA. Prevalence and causes of anaemia in a geriatric hospitalized population. Gerontology 1992; 38(1-2): 111-17.
11. Smith DL. Anemia in the elderly. Am Fam Physician 2000; 62(7): 1565-72.
12. Gabrilove J. Anemia and the elderly: clinical considerations. Best Pract Res Clin Haematol 2005; 18(3): 417-22.
13. Guralnik JM, Eisenstaedt RS, Ferrucci L, Klein HG, Woodman RC. Prevalence of anemia in persons 65 years and older in the United States: evidence for a high rate of unexplained anemia. Blood 2004; 104(8): 2263-8.
14. Zakai NA, Katz R, Hirsch C, Shlipak MG, Chaves PH, Newman AB, et al. A prospective study of anemia status, hemoglobin concentration, and mortality in an elderly cohort: the cardiovascular health study. Arch Intern Med 2005; 165(19): 2214-20.
15. Landi F, Russo A, Danese P, Lipreri T, Barillaro C, Bernabei R, et al. Anemia status, hemoglobin concentration, and mortality in nursing home older residents. J Am Med Dir Assoc 2007; 8(5): 322-7.
16. Horwich TB, Fonarow GC, Hamilton MA, MacLellan WR, Borenstein J. Anemia is associated with worse symptoms, greater impairment in functional capacity and a significant increase in mortality in patients with advanced heart failure. J Am Coll Cardiol 2002; 39(11): 1780-6.
17. Penninx BW, Guralnik JM, Onder G, Ferrucci L, Wallace RB, Pahor M. Anemia and decline in physical performance among older persons. Am J Med 2003; 115(2): 104-10.
18. Wilkinson TJ, Warren MR, What is the prognosis of mild normocytic anaemia in older people? Intern Med J 2003; 33(1-2): 14-17.
19. Penninx BW, Pluijm SM, Lips P, Woodman R, Miedema K, Guralnik JM, et al. Late-life anemia is associated with increased risk of recurrent falls. J Am Geriatr Soc 2005; 53(12): 2106-11.
20. Chaves PH, Somba RD, Leng SX, Woodman RC, Ferrucci L, Guralnik JM, et al. Impact of anemia and cardiovascular disease on frailty status of community-dwelling older women: the women’s health and aging studies I and II. J Gerontol A Biol Sci Med Sci 2005; 60(6): 729-35.
21. Weiss G, Goodnough LT. Anemia of chronic disease. N Engl J Med 2005; 352(10): 1011-23.
22. Mattei AM, Walston JD, Fallin MD, Bandeen-Roche K, Kao WH, Somba RD, et al. Markers of B-vitamin deficiency and frailty in older women. J Nutr Health Aging 2008; 12(5): 303-8.
23. Ferrucci L, Maggio M, Bandinelli S, Basaria S, Lauretani F, Ble A, et al. Low testosterone levels and the risk of anemia in older men and women. Arch Intern Med 2006; 166(13): 1380-8.
24. Holick MF, Frommer JE, McNeill SC, Richtand NM, Henley JW, Potts JT, Jr. Photometabolism of 7-dehydrocholesterol to previtamin D3 in skin. Biochem Biophys Res Commun 1977; 76(1): 107-14.
25. Cheng JB, Motola DL, Mangelsdorf DJ, Russell DW. De-orphanization of cytochrome P450 2R1: a microsomal vitamin D 25-hydroxilase. J Biol Chem 2003; 278(39): 38084-93.
26. Holick MF. The cutaneous photosynthesis of vitamin D3: a unique photoendocrine system. J Invest Dermatol 1981; 77(1): 51-8.
27. Nykjaer A, Dragon D, Walther D, Vorum H, Jacobsen C, Herz J, et al. An endocytic pathway essential...
for renal uptake and activation of the steroid 25-(OH) vitamin D3. Cell 1999; 96(4): 507-15.

28. Hewison M, Zehnder D, Chakraverty R, Adams JS. Vitamin D and barrier function: a novel role for extra-renal 1 alpha-hydroxylase. Mol Cell Endocrinol 2004; 215(1-2): 31-8.

29. Brown AJ, Dusso A, Slapolsky E. Vitamin D. Am J Physiol 1999; 277(2 Pt 2): F157-F175.

30. Nemere I, Yoshimoto N, Norman AW. Calcium transport in perfused duodena from normal chicks: enhancement within fourteen minutes of exposure to 1, 25-dihydroxyvitamin D3. Endocrinology 1984; 115(4): 1476-83.

31. Hoenderop JG, Willems PH, Bindels RJ. Toward a comprehensive molecular model of active calcium reabsorption. Am J Physiol Renal Physiol 2000; 278(3): F352-F360.

32. Dusso AS, Brown AJ, Slapolsky E. Vitamin D. Am J Physiol Renal Physiol 2005; 289(1): F8-28.

33. Grant WB, Holick MF. Benefits and requirements of vitamin D for optimal health: a review. Altern Med Rev 2005; 10(2): 94-111.

34. Adams JS, Hewison M. Update in vitamin D. J Clin Endocrinol Metab 2010; 95(2): 471-8.

35. Calvo MS, Whiting SJ. Prevalence of vitamin D insufficiency in Canada and the United States: importance to health status and efficacy of current food fortification and dietary supplement use. Nutr Rev 2003; 61(3): 107-13.

36. Tangpricha V, Pearce EN, Chen TC, Holick MF. Vitamin D insufficiency among free-living healthy young adults. Am J Med 2002; 112(8): 659-62.

37. Trivedi DP, Doll R, Khaw KT. Effect of four monthly oral vitamin D3 (cholecalciferol) supplements on fractures and mortality in men and women living in the community: randomised double blind controlled trial. BMJ 2003; 326(7387): 469.

38. Bischoff-Ferrari HA, Dawson-Hughes B, Staehelin HB, Orav JE, Stuck AE, Theiler R, et al. Fall prevention with supplemental and active forms of vitamin D: a meta-analysis of randomised controlled trials. BMJ 2009; 339: b3692.

39. Bunout D, Barrera G, Leiva L, Gattas V, de la Maza MP, Avendano M, et al. Effects of vitamin D supplementation and exercise training on physical performance in Chilean vitamin D deficient elderly subjects. Exp Gerontol 2006; 41(8): 746-52.

40. Wicherts IS, van Schoor NM, Boeke AJ, Visser M, Deeg DJ, Smit J, et al. Vitamin D status predicts physical performance and its decline in older persons. J Clin Endocrinol Metab 2007; 92(6): 2058-65.

41. Roth HJ, Schmidt-Gayk H, Weber H, Niederau C. Accuracy and clinical implications of seven 25-hydroxyvitamin D methods compared with liquid chromatography-tandem mass spectrometry as a reference. Ann Clin Biochem 2008; 45(Pt 2): 153-9.

42. Mooradian AD. Asymptomatic hyperthyroidism in older adults: is it a distinct clinical and laboratory entity? Drugs Aging 2008; 25(5): 371-80.

43. Biondi B, Cooper DS. The clinical significance of subclinical thyroid dysfunction. Endocr Rev 2008; 29(1): 76-131.

44. Wilson GR, Curry RW, Jr. Subclinical thyroid disease. Am Fam Physician 2005; 72(8): 1517-24.

45. van den Beld AW, Visser TJ, Feelders RA, Grobbee DE, Lambertsw SW. Thyroid hormone concentrations, disease, physical function, and mortality in elderly men. J Clin Endocrinol Metab 2005; 90(12): 6403-9.

46. Weisell M. Disturbances of thyroid function in the elderly. Wien Klin Wochenschr 2006; 118(1-2): 16-20.

47. Habra M, Sarlis NJ. Thyroid and aging. Rev Endocr Metab Disord 2005; 6(2): 145-54.

48. Dominguez LJ, Bevilacqua M, Dibella G, Barbagallo M. Diagnosing and managing thyroid disease in the nursing home. J Am Med Dir Assoc 2008; 9(1): 9-17.

49. Nawroth PP, Ziegler R. Klinische Endocrinology und Stoffwechsel. Berlin: springer verlag; 2001. p. 243-320.

50. Tariq SH, Haren MT, Kim MJ, Morley JE. Andropause: is the emperor wearing any clothes? Rev Endocr Metab Disord 2005; 6(2): 77-84.

51. Valenti G. Frailty as a dysruption of steroid "synchronology" in elderly man. Acta Biomed 2007; 78 Suppl 1: 222-4.

52. Bischoff-Ferrari HA, Dawson-Hughes B, Willett WC, Staehelin HB, Bazemore MG, Zee RY, et al. Effect of vitamin D on falls: a meta-analysis. JAMA 2004; 291(16): 1999-2006.

53. Ceda GP, Dall’Aglie E, Maggio M, Lauretani F, Bandinelli S, Falsasi C, et al. Clinical implications of the reduced activity of the GH-IGF-I axis in older men. J Endocrinol Invest 2005; 28(11 Suppl Proceedings): 96-100.

54. Maggio M, Cappola AR, Ceda GP, Basaria S, Chia CW, Valenti G, et al. The hormonal pathway to frailty in older men. J Endocrinol Invest 2005; 28(11 Suppl Proceedings): 15-19.

55. Mohr BA, Bhasin S, Kupelian V, Araujo AB, O’Donnell AB, McKinlay JB. Testosterone, sex hormone-binding globulin, and frailty in older men. J Am Geriatr Soc 2007; 55(4): 548-55.

56. Morley JE, Baumgartner RN. Cytokine-related aging process. J Gerontol A Biol Sci Med Sci 2004; 59(9): M924-M929.

57. Morley JE, Thomas DR. Cachexia: new advances in the management of wasting diseases. J Am Med Dir Assoc 2008; 9(4): 205-10.

58. Morley JE, Thomas DR, Wilson MM. Cachexia: pathophysiology and clinical relevance. Am J Clin Nutr 2006; 83(4): 735-43.

59. Yeh SS, Blackwood K, Schuster MW. The cytokine basis of cachexia and its treatment: are they ready for prime time? J Am Med Dir Assoc 2008; 9(4): 219-36.

60. Bertsch T, Banks RE, Forbes MA, Aufenanger J, Storr M, Illingworth JM, et al. Phospholipase A2
activity in serum is induced during treatment with recombinant human interleukin-6 in patients with cancer. Ann Clin Biochem 1996; 33 (Pt 6): 565-7.

61. Leng SX, Xue QL, Tian J, Walston JD, Fried LP. Inflammation and frailty in older women. J Am Geriatr Soc 2007; 55(6): 864-71.

62. Hubbard RE, O'Mahony MS, Calver BL, Woodhouse KW. Nutrition, inflammation, and leptin levels in aging and frailty. J Am Geriatr Soc 2008; 56(2): 279-84.

63. Walston J, McBurnie MA, Newman A, Tracy RP, Kop WJ, Hirsch CH, et al. Frailty and activation of the inflammation and coagulation systems with and without clinical comorbidities: results from the cardiovascular health study. Arch Intern Med 2002; 162(20): 2333-41.

64. Bauer JM, Sieber CC. Sarcopenia and frailty: a clinician’s controversial point of view. Exp Gerontol 2008; 43(7): 674-8.

65. De Martinis M, Franceschi C, Monti D, Ginaldi L. Inflammation markers predicting frailty and mortality in the elderly. Exp Mol Pathol 2006; 80(3): 219-27.